Jul 5, 2023
Chris Hoyt, CEO of KeifeRx, talks about the oral medication being developed that uses tyrosine kinase inhibitors (TKIs) and autophagy to remove unwanted proteins. Research done by Georgetown University on leukemia, led by Dr. Charbel Moussa, found that lower doses of drugs like nilotinib and bosutinib could cross the...
Jul 5, 2023
Chris Hoyt, CEO of KeifeRx, talks about the oral medication being developed that uses tyrosine kinase inhibitors (TKIs) and autophagy to remove unwanted proteins. Research done by Georgetown University on leukemia, led by Dr. Charbel Moussa, found that lower doses of drugs like nilotinib and bosutinib could cross the...
Mar 28, 2023
Benjamin Lightburn, Co-Founder and CEO of Filament Health points out that up until now, research with psychedelics has been done with synthetically prepared psychedelic substances. Filament is making a product through natural extraction that results in a medicine containing psilocybin plus over a dozen other active...
Mar 28, 2023
Benjamin Lightburn, Co-Founder and CEO of Filament Health points out that up until now, research with psychedelics has been done with synthetically prepared psychedelic substances. Filament is making a product through natural extraction that results in a medicine containing psilocybin plus over a dozen other active...
Mar 21, 2023
David Bearss the Co-Founder, CEO and President of Halia Therapeutics, points out that despite traditional thinking, chronic inflammation is not just an unresolved acute inflammatory response. It has been discovered that a different pathway leads to the activation of this inflammatory response in diseases with components...